Chiesi Farmaceutici S.p.A. acquires KalVista Pharmaceuticals, Inc. (2026)

Deal facts

Buyer: Chiesi Farmaceutici S.p.A.
Target: KalVista Pharmaceuticals, Inc.
Deal value: Not disclosed
Announced: 29 April 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

What we know

Chiesi Farmaceutici S.p.A. has agreed to acquire KalVista Pharmaceuticals, Inc. in a going private transaction structured as a cash consideration deal. The Italian healthcare company announced the agreement on 29 April 2026, with the target being a US-based biotechnology firm operating within the healthcare sector. The transaction was completed on 11 June 2026, marking the end of the public listing for the acquired entity. No specific deal value was reported in the available data.

The acquisition represents a strategic move by the buyer to integrate the target's assets into its existing portfolio. This deal concludes the period during which KalVista Pharmaceuticals operated as an independent public company. The transaction is now final following the completion date.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

11 Jun 2026CompletedClosed
Chiesi Farmaceutici S.p.A. completes acquisition of KalVista Pharmaceuticals, Inc.
Introductory Note On April 29, 2026, we previously reported with the U.S. Securities and Exchange Commission (the “SEC”) that KalVista Pharmaceuticals, Inc., a Delaware corporation (“ us ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), dated April 29, 2026, with Chiesi Farmaceutici S.p.A., an Italian società per azioni (“ Parent ”), Skyline Merger Sub
Source

OpinionExit Mode editorial

We see a clear signal in the completion of Chiesi Farmaceutici's acquisition of KalVista Pharmaceuticals. This transaction moves a US-listed biotech firm into private ownership under an Italian pharmaceutical group. The deal structure is straightforward: a cash consideration that removes the target from public markets entirely. For the SME founder watching from the UK or Europe, this highlights a growing trend where specialist industrial groups prefer full control over high-potential assets rather than navigating the complexities of public market scrutiny.

The shift from public to private status carries specific regulatory and commercial implications that founders must weigh before signing. A cross-border deal of this nature, involving a US target and an EU buyer, inevitably triggers competition reviews. In this instance, the European Commission or the US Federal Trade Commission would have assessed whether the combination created anti-trust issues. Furthermore, the move to a going-private transaction requires strict adherence to securities laws in the target's jurisdiction. The buyer must secure shareholder approval and manage the delisting process with precision. These are not mere formalities; they are the gates that determine if a deal closes or stalls.

We think the choice of an all-cash offer is particularly telling. It suggests the buyer values speed and certainty over complex earn-out structures or contingent value rights. For a founder, this removes the risk of future performance targets failing to unlock additional value. However, it also means the entire valuation is locked in at the announcement. There is no room for the target to benefit from a share-price rally post-announcement. The seller trades upside potential for immediate liquidity and the security of a completed transaction.

The takeaway for any founder considering a sale this week is to audit your current regulatory exposure before engaging a buyer. If your business operates in a regulated sector like healthcare, map out the competition thresholds in both your home market and the buyer's jurisdiction. Do not assume a cash offer guarantees a smooth path to completion. Ensure your legal team has already identified the specific anti-trust or change-of-control covenants that could delay the deal, so you can negotiate a timeline that reflects the true complexity of the clearance process.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from Chiesi Farmaceutici S.p.A.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

28 July 2026CompletedHealthcare

CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC

CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…

Buyer: CCP PAW 2 LIMITED
Target: ANIMALCARE GROUP PLC
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United Kingdom deals

26 July 2026CompletedHealthcare

argenx BV to acquire Forte Biosciences, Inc.

argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing…

Buyer: argenx BV
Target: Forte Biosciences, Inc.
Deal value: USD 2,200,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6…

Buyer: Vertex Pharmaceuticals Incorporated
Target: Crinetics Pharmaceuticals, Inc.
Deal value: USD 10,000,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

Buyer history